ICE-T Conference presenters explain what nurses and APPs should take into account as immune cell effector therapies become ...

Researchers studied the relationship between lymphovascular invasion and adverse outcomes in patients with cutaneous squamous cell carcinoma.

On June 1, Allogene Therapeutics Inc. (NASDAQ: ALLO) presented updated data from the Phase 1 TRAVERSE study of ALLO-316 in advanced or metastatic renal cell carcinoma/RCC during an oral ...

ALLO-316 shows promising response rates in advanced renal cell carcinoma, utilizing Dagger technology for enhanced CAR T cell efficacy.

Background: Renal cell carcinoma (RCC) is a leading cause of cancer-related mortality, with a rapidly rising global incidence. Early detection greatly improves the outcomes of RCC, yet current ...

Neoadjuvant lenvatinib plus pembrolizumab for resectable clear-cell renal cell carcinoma (PELUR): A prospective phase 2 study.. If you have the appropriate software installed, you can download article ...

Renal cell carcinoma highlights from ASCO GU 2025 include follow-up data from the CheckMate 9ER study, updated COSMIC-313 results, and promising early data on casdatifan, a new HIF-2 alpha inhibitor.

For patients with primary localized renal cell carcinoma (RCC), especially those who aren’t good candidates for surgery, noninvasive or minimally invasive ablative treatments have emerged as ...

The study enrolled nine patients with stage 3 and 4 clear cell renal cell carcinoma, who experienced successful anti-cancer immune responses associated with the vaccine. “This approach is truly ...

Background: Renal cell carcinoma (RCC) is one of the most lethal urological malignancies, and because early-stage RCC is asymptomatic, many patients present metastatic diseases at first diagnosis.